Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer

Basit Öğe Kaydı
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorErdogan, Bulent
dc.contributor.authorKostek, Osman
dc.contributor.authorBekirhacioglu, Muhammet
dc.date.accessioned2024-06-12T10:55:12Z
dc.date.available2024-06-12T10:55:12Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractProstate carcinoma is androgen-dependent, and therefore the main target of treatment is lowering androgen levels. Medical or surgical castration, androgen receptor-blocking agents, androgen-synthesis inhibitors, chemotherapy, sipuleucel-T, and radium-223 are treatment options. Enzalutamide is a relatively new androgen-signaling inhibitor that has 5 to 8 times greater affinity for the androgen receptor ( AR) than bicalutamide. Enzalutamide does not demonstrate agonistic activity on ARs. Enzalutamide induces apoptosis of prostate cancer cells. Enzalutamide is effective in metastatic castration-resistant prostate cancer in patients with progression after docetaxel treatment and in chemotherapy-naive patients. Enzalutamide is also superior to the commonly used AR blocking agent bicalutamide in chemotherapy-naive metastatic and non-metastatic castration-resistant prostate cancer patients. Its efficacy has been proven in hormonenaive patients, and several trials are ongoing. Enzalutamide has a favorable side effect profile and improves quality of life and pain scores. There are ongoing studies examining the efficacy and safety of enzalutamide on other several AR-expressing tumors.en_US
dc.identifier.doi10.14744/ejmo.2018.72098
dc.identifier.endpage129en_US
dc.identifier.issn2587-196X
dc.identifier.issue3en_US
dc.identifier.startpage121en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2018.72098
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19335
dc.identifier.volume2en_US
dc.identifier.wosWOS:000604241600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectEnzalutamideen_US
dc.subjectProstate Canceren_US
dc.subjectAndrogen Receptor Expressionen_US
dc.subjectOpen-Labelen_US
dc.subjectAntitumor-Activityen_US
dc.subjectCastrationen_US
dc.subjectBicalutamideen_US
dc.subjectSafetyen_US
dc.subjectMonotherapyen_US
dc.subjectEfficacyen_US
dc.subjectResistanceen_US
dc.subjectOutcomesen_US
dc.titleEnzalutamide in Prostate Cancer, A Review on Enzalutamide and canceren_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu